Cardiovascular Drug Contraindications & Indications – 40+ Verified Facts on Antihypertensives, Anticoagulants, Statins – Pharm 2025

This expert-verified flashcard-style review compiles over 40 high-yield pharmacologic facts focused on contraindications (CIs), treatment goals, and indications of essential cardiovascular drugs. Tailored to the Pharm 2025 curriculum, this document is perfect for last-minute review and quick recall of critical testable points across antihypertensives, antithrombotics, and lipid-lowering agents. Key learning points include: Contraindications (CIs) for common cardiovascular drugs: Diuretics: CA inhibitors, loop diuretics, thiazides, and K⁺-sparing agents – linked to hypokalemia, gout, DM, and hyperkalemia Beta blockers: CI in asthma and COPD RAAS inhibitors: ACEIs, ARBs, renin inhibitors – all Pregnancy Category D Warfarin and Statins: Pregnancy Category X Niacin: contraindicated in gout Treatment goals: Normal BP: <120/80 HTN patients: <140/90 HTN with diabetes, CKD, or albuminuria: <130/80 Lipid management: Statins: most effective for LDL reduction Fibrates: best for lowering triglycerides Niacin: raises HDL the most Pregnancy-safe drugs: Methyldopa for HTN Bile acid-binding resins for hypercholesterolemia Antidotes and Indications: Warfarin → phytonadione, UFH/LMWH → protamine sulfate Thrombolytics → aminocaproic acid Dabigatran → Praxibind Ticagrelor → ACS, Ticlodipine → stroke prevention This guide is perfect for: Medical, nursing, and pharmacy students reviewing high-yield pharmacology USMLE Step 1, NAPLEX, NCLEX-RN, and Pharm 2025 final exam prep Quick-reference learning of drug safety and therapeutic targets Keywords: cardiovascular pharmacology, drug contraindications, pregnancy category X, ACE inhibitors, ARBs, beta blockers, statins, warfarin, anticoagulant antidotes, thrombolytics, antihypertensives, salicylic acid, niacin, methyldopa, fondaparinux, ticagrelor, dabigatran, blood pressure goals, lipid-lowering therapy, Pharm 2025